SCHEMBL3552547

SCHEMBL3552547

CC1CC(O)(c2ccccc2)CN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
OPRM1 P35372 6/20 0.41
OPRL1 P41146 6/20 0.41
OPRK1 P41145 4/20 0.41
GRIN2B Q13224 4/20 0.38
OPRD1 P41143 2/20 0.37
HRH2 P25021 1/20 0.37
GPR183 P32249 1/20 0.37
MAPT P10636 1/20 0.36
F2 P00734 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18703580 0.84 OPRM1 (0.43) SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL18689560 0.82 OPRM1 (0.42) SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3
SCHEMBL11534597 0.82 DRD2 (0.47) SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3
SCHEMBL3545378 0.77 GRIN2B (0.43) OPRM1OPRL1OPRK1GRIN2BOPRD1
SCHEMBL4390692 0.77 HTR2A (0.42) SLC6A2SLC6A3CHRNB2CHRNB4CHRNA3
SCHEMBL10576425 0.75 F2 (0.44) OPRM1OPRL1OPRK1GRIN2BMAPT
SCHEMBL7864750 0.75 F2 (0.44) OPRM1OPRL1OPRK1GRIN2BMAPT
SCHEMBL3060343 0.75 F2 (0.44) OPRM1OPRL1OPRK1GRIN2BMAPT
SCHEMBL23259077 0.74 OPRM1 (0.47) SLC6A2SLC6A3OPRM1OPRL1OPRK1
SCHEMBL12166535 0.73 F2 (0.47) OPRM1OPRL1OPRK1GRIN2BF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 SLC6A2 3032/4885SLC6A3 2642/4885CHRNB2 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.